Drugs / RP3128
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02958982 | Nov 2016 → Feb 2018 | asthma | Rhizen Pharmaceuticals SA | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RP3128 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02958982 ↗ |
| Route | Oral | “RP3128, an oral calcium release-activated calcium (CRAC) channel modulator” PMID 33314326 ↗ Dec 2020 |